Results 161 to 170 of about 1,031,574 (396)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Minireview: Ubiquitination-regulated G Protein-Coupled Receptor Signaling and Trafficking [PDF]

, 2013
Verónica Alonso, Peter A. Friedman
openalex   +1 more source

Targeting G protein–coupled receptor kinases to G protein–coupled receptors

Current Opinion in Endocrine and Metabolic Research, 2021
Sarah M. Sulon, Jeffrey L. Benovic
openaire   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

The Chain Length Dependence of Helix Formation of the Second Transmembrane Domain of a G Protein-coupled Receptor ofSaccharomyces cerevisiae

, 2002
Fa‐Xiang Ding, David Schreiber, Nathan C. VerBerkmoes, Jeffrey M. Becker, Fred Naider   +4 more
openalex   +1 more source

Putative Active States of a Prototypic G-Protein-Coupled Receptor from Biased Molecular Dynamics [PDF]

, 2010
Davide Provasi, Marta Filizola
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

G protein coupled receptor in apoptosis and apoptotic cell clearance

FASEB BioAdvances
Apoptosis is a genetically programmed form of cell death that is substantially conserved across the evolutionary tree. Apoptotic cell elimination includes recognition, phagocytosis, and degradation. Failure to clear apoptotic cells can ultimately cause a
Xinyan Li, Chao Li, Yang Kang, Rui Zhang, Peiyao Li, Qian Zheng, Hui Wang, Hui Xiao, Lei Yuan   +8 more
doaj   +1 more source

Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas

Proceedings of the National Academy of Sciences of the United States of America, 2003
R. Santos, A. C. S. e Silva, C. Maric, Denise M. R. Silva, Raquel P. Machado, I. de Buhr, S. Heringer-walther, S. Pinheiro, M. T. Lopes, M. Bader, E. P. Mendes, V. S. Lemos, M. Campagnole-Santos, H. Schultheiss, R. Speth, T. Walther   +15 more
semanticscholar   +1 more source

Identification of a novel synaptic G protein-coupled receptor controlling nicotine dependence and withdrawal

, 2015
Beatriz Antolin Fontes
openalex   +2 more sources